, Tracking Stock Market Picks
Enter Symbol:
Rating: AVII
Sector Perform $15

Sarepta Therapeutics Inc (NASDAQ: SRPT) reiterated to Sector Perform with price target $15 by RBC Capital Mkts

Tuesday,  Jan 19, 2016  8:25 AM ET by Kristen Bailey

RBC Capital Mkts reiterated Sarepta Therapeutics Inc (NASDAQ: SRPT) to Sector Perform with
price target $15. RBC Capital Mkts rated Sarepta Therapeutics Inc (NASDAQ: SRPT) to Sector Perform with price target $15 on 01/23/2015, when the price was $12.05.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy